Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(10):1248–1254. doi: 10.1038/bjc.1996.239

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.

M Díez 1, A Torres 1, M L Maestro 1, M D Ortega 1, A Gómez 1, M Pollán 1, J A Lopez 1, A Picardo 1, F Hernando 1, J L Balibrea 1
PMCID: PMC2074500  PMID: 8630287

Abstract

Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients were analysed with respect of TNM stage, histological type and carcinoembryonic antigen (CEA), CA125 antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually complementary. We conclude that CA125 and CEA complement TNM classification and histological type for the purpose of quantifying risk of death or recurrence.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bains M. S. Surgical treatment of lung cancer. Chest. 1991 Sep;100(3):826–837. doi: 10.1378/chest.100.3.826. [DOI] [PubMed] [Google Scholar]
  2. Bergman B., Brezicka F. T., Engström C. P., Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer. 1993;29A(2):198–202. doi: 10.1016/0959-8049(93)90174-e. [DOI] [PubMed] [Google Scholar]
  3. Carney D. N. Lung cancer biology. Eur J Cancer. 1991;27(3):366–369. doi: 10.1016/0277-5379(91)90547-q. [DOI] [PubMed] [Google Scholar]
  4. Diez M., Gomez A., Hernando F., Ortega M. D., Maestro M. L., Torres A., Mugüerza J. M., Gutierrez A., Granell J., Balibrea J. L. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer. Int J Biol Markers. 1995 Jan-Mar;10(1):5–10. doi: 10.1177/172460089501000102. [DOI] [PubMed] [Google Scholar]
  5. Diez M., Torres A., Pollán M., Gomez A., Ortega D., Maestro M. L., Granell J., Balibrea J. L. Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer. 1994 Mar 1;73(5):1368–1376. doi: 10.1002/1097-0142(19940301)73:5<1368::aid-cncr2820730510>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  6. Fielding L. P., Fenoglio-Preiser C. M., Freedman L. S. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992 Nov 1;70(9):2367–2377. doi: 10.1002/1097-0142(19921101)70:9<2367::aid-cncr2820700927>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  7. Gail M. H., Eagan R. T., Feld R., Ginsberg R., Goodell B., Hill L., Holmes E. C., Lukeman J. M., Mountain C. F., Oldham R. K. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 1984 Nov 1;54(9):1802–1813. doi: 10.1002/1097-0142(19841101)54:9<1802::aid-cncr2820540908>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  8. Järvisalo J., Hakama M., Knekt P., Stenman U. H., Leino A., Teppo L., Maatela J., Aromaa A. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer. 1993 Mar 15;71(6):1982–1988. doi: 10.1002/1097-0142(19930315)71:6<1982::aid-cncr2820710610>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  9. Lee J. S., Hong W. K. Prognostic factors in lung cancer. N Engl J Med. 1992 Jul 2;327(1):47–48. doi: 10.1056/NEJM199207023270110. [DOI] [PubMed] [Google Scholar]
  10. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  11. Murren J. R., Buzaid A. C. Chemotherapy and radiation for the treatment of non-small-cell lung cancer. A critical review. Clin Chest Med. 1993 Mar;14(1):161–171. [PubMed] [Google Scholar]
  12. Picardo A. L., Torres A. J., Maestro M., Ortega D., Garcia-Asenjo J. A., Mugüerza J. M., Hernando F., Diez M., Balibrea J. L. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer. Cancer. 1994 May 1;73(9):2305–2311. doi: 10.1002/1097-0142(19940501)73:9<2305::aid-cncr2820730911>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  13. Shepherd F. A. Future directions in the treatment of non-small cell lung cancer. Semin Oncol. 1994 Jun;21(3 Suppl 4):48–62. [PubMed] [Google Scholar]
  14. Shinkai T., Saijo N., Tominaga K., Eguchi K., Shimizu E., Sasaki Y., Fujita J., Futami H., Ohkura H., Suemasu K. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 1986 Apr 1;57(7):1318–1323. doi: 10.1002/1097-0142(19860401)57:7<1318::aid-cncr2820570711>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  15. Spiridonidis C. H., Laufman L. R., Stydnicki K. A., Noltimier J. W., Cho C. C., Young D. C., Hicks W. J., Segal M. L., Guy J. T., Zidar B. L. Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer. 1995 Apr 1;75(7):1586–1593. doi: 10.1002/1097-0142(19950401)75:7<1586::aid-cncr2820750706>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  16. Strauss G. M., Kwiatkowski D. J., Harpole D. H., Lynch T. J., Skarin A. T., Sugarbaker D. J. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol. 1995 May;13(5):1265–1279. doi: 10.1200/JCO.1995.13.5.1265. [DOI] [PubMed] [Google Scholar]
  17. Strauss G. M., Skarin A. T. Use of tumor markers in lung cancer. Hematol Oncol Clin North Am. 1994 Jun;8(3):507–532. [PubMed] [Google Scholar]
  18. Sánchez De Cos J., Masa F., de la Cruz J. L., Disdier C., Vergara C. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest. 1994 Mar;105(3):773–776. doi: 10.1378/chest.105.3.773. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES